Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Michael T. Jaklitsch, M.D.

Co-Author

This page shows the publications co-authored by Michael Jaklitsch and Harvey Mamon.
Connection Strength

0.249
  1. Mamon HJ, Yeap BY, Jänne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005 Mar 01; 23(7):1530-7.
    View in: PubMed
    Score: 0.085
  2. Mamon HJ, Yeap B, Reblando J, Shrager S, Jaklitsch MT, Lukanich JM, Sugarbaker DJ, Baldini E, Janne P, Bueno R. High risk of brain metastases in surgically staged IIIA NSCLC patients treated with surgery, chemotherapy and radiation. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7173.
    View in: PubMed
    Score: 0.081
  3. Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468.
    View in: PubMed
    Score: 0.046
  4. Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.